William J. Gradishar, MD: Controlling Metastatic Disease
Watch
Triple-Negative Breast Cancer: Case 2
Triple-Negative Breast Cancer
Denise A. Yardley, MD: Standard of Care for Patient
Denise A. Yardley, MD: Main Choices for TNBC
Denise A. Yardley, MD: Chemotherapy Combinations with TNBC
William J. Gradishar, MD: Standard of Care for Patient
William J. Gradishar, MD: Main Choices for TNBC
William J. Gradishar, MD: Chemotherapy Combinations with TNBC
Triple-Negative Breast Cancer: Case 1
Philip Kantoff, MD: Safety Considerations Regarding Treatment
Philip Kantoff, MD: Consideration of Chemotherapy
Philip Kantoff, MD: Second-Line Hormonal Therapy
Philip Kantoff, MD: Treatments to Prolong Survival
Charles J. Ryan, MD: Safety Considerations Regarding Treatment
Charles J. Ryan, MD: Consideration of Chemotherapy
Charles J. Ryan, MD: Second-Line Hormonal Therapy
Charles J. Ryan, MD: Treatments to Prolong Survival
Metastatic Castration-Resistant Prostate Cancer Issue 2: Case 2
Metastatic Castration-Resistant Prostate Cancer Issue 2
Philip Kantoff, MD: Additional Treatment Options Following Immunotherapy
Charles J. Ryan, MD: Additional Treatment Options Following Immunotherapy
Metastatic Castration-Resistant Prostate Cancer Issue 2: Case 1
Future of Immunotherapy in Various Tumor Types
Benjamin G. Neel, MD, faculty, Department of Medicine, Perlmutter Cancer Center, NYU School of Medicine, discusses the future of immunotherapy and how it could play a role in various tumor types.
Krishnansu S. Tewari, MD, FACOG, FACS: Data in Support of Adding Antiangiogenesis Therapy To Current Treatment
Krishnansu S. Tewari, MD, FACOG, FACS: Adding Bevacizumab to Cisplatin/Paclitaxel in Patient
Krishnansu S Tewari, MD, FACOG, FACS: Patient Characteristics to Consider
Krishnansu S Tewari, MD, FACOG, FACS: Safety Concerns Regarding Treatment
